Why the study?
Resistant hypertension remains high-risk and difficult to treat, driving a pressing need for novel antihypertensive classes acting on new therapeutic targets like aminopeptidase A in the brain renin-angiotensin system.
Are centrally acting APA inhibitors safe and effective in reducing blood pressure in patients with hypertension?
Population
Patients with hypertension in published phase I-II literature
Comparison
APA inhibitors (including firibastat) evaluated for safety and efficacy
Design
Narrative review of clinical trials
Authors
Loading...
May lower BP in resistant hypertension; leaves open need for randomized confirmation before practice change.
Are centrally acting APA inhibitors safe and effective in reducing blood pressure in patients with hypertension?
Firibastat, a novel brain aminopeptidase A inhibitor, represents a potential new class of centrally acting antihypertensive drugs for the management of hypertension.
Alomar et al. (2021) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: